Tonix Pharmaceuticals Holding Corp.

DB:TPM0 Stock Report

Market Cap: €11.8m

Tonix Pharmaceuticals Holding Past Earnings Performance

Past criteria checks 0/6

Tonix Pharmaceuticals Holding's earnings have been declining at an average annual rate of -36.3%, while the Biotechs industry saw earnings growing at 16.9% annually.

Key information

-36.3%

Earnings growth rate

115.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-70.6%
Net Marginn/a
Last Earnings Update31 Mar 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Tonix Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:TPM0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 230-1233090
31 Dec 220-1173082
30 Sep 220-1122979
30 Jun 220-1022770
31 Mar 220-982672
31 Dec 210-922369
30 Sep 210-802159
30 Jun 210-731954
31 Mar 210-641747
31 Dec 200-521436
30 Sep 200-461230
30 Jun 200-421226
31 Mar 200-341119
31 Dec 190-311118
30 Sep 190-311018
30 Jun 190-281016
31 Mar 190-29916
31 Dec 180-29918
30 Sep 180-24816
30 Jun 180-24817
31 Mar 180-23816
31 Dec 170-21813
30 Sep 170-23915
30 Jun 170-25915
31 Mar 170-30921
31 Dec 160-391029
30 Sep 160-451233
30 Jun 160-501339
31 Mar 160-521339
31 Dec 150-481336
30 Sep 150-441232
30 Jun 150-381127
31 Mar 150-321022
31 Dec 140-28919
30 Sep 140-22814
30 Jun 140-18711
31 Mar 140-1477
31 Dec 130-1165
30 Sep 130-1054
30 Jun 130-853
31 Mar 130-953
31 Dec 120-943

Quality Earnings: TPM0 is currently unprofitable.

Growing Profit Margin: TPM0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TPM0 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.

Accelerating Growth: Unable to compare TPM0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TPM0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: TPM0 has a negative Return on Equity (-70.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies